Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 6,180,200 | 5,209,900 | 2,242,900 | 5,240,400 | 3,050,700 |
| Depreciation Amortization | 1,281,800 | 815,000 | 400,600 | 1,527,300 | 1,139,600 |
| Income taxes - deferred | -1,716,400 | -1,286,600 | -279,000 | -2,341,000 | -1,834,800 |
| Accounts receivable | N/A | N/A | N/A | -2,451,000 | N/A |
| Accounts payable and accrued liabilities | N/A | N/A | N/A | 4,274,400 | N/A |
| Other Working Capital | 234,600 | -3,150,300 | -1,751,200 | -3,055,000 | 103,200 |
| Other Operating Activity | 363,900 | 1,044,200 | 552,700 | 1,045,000 | 2,093,300 |
| Operating Cash Flow | $6,344,100 | $2,632,200 | $1,166,000 | $4,240,100 | $4,552,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 38,700 | 26,600 | 17,000 | 94,000 | 76,000 |
| PPE Investments | -3,561,800 | -2,211,100 | -986,300 | -3,447,600 | -2,377,000 |
| Net Acquisitions | -947,700 | -947,700 | N/A | -1,044,300 | N/A |
| Purchase Of Investment | -525,100 | -250,100 | -117,100 | -730,800 | -474,800 |
| Sale Of Investment | 318,000 | 250,100 | 70,500 | 508,100 | 476,200 |
| Purchase Sale Intangibles | 530,900 | N/A | N/A | N/A | 1,604,300 |
| Other Investing Activity | -2,703,100 | -244,100 | -161,700 | -2,532,100 | -1,928,800 |
| Investing Cash Flow | $-7,381,000 | $-3,376,300 | $-1,177,600 | $-7,152,700 | $-4,228,400 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -4,894,100 | -1,804,700 | -5,204,800 | N/A | 97,000 |
| Debt Issued | 11,417,100 | 6,452,500 | 6,452,500 | 8,649,900 | 3,958,500 |
| Debt Repayment | -664,200 | -664,200 | N/A | N/A | N/A |
| Common Stock Repurchased | -446,100 | N/A | N/A | -750,000 | -750,000 |
| Dividend Paid | -3,512,100 | -2,341,600 | -1,169,200 | -4,069,300 | -3,051,200 |
| Other Financing Activity | -445,100 | -397,800 | -389,800 | -335,000 | -303,400 |
| Financing Cash Flow | $1,455,500 | $1,244,200 | $-311,300 | $3,495,600 | $-49,100 |
| Exchange Rate Effect | 131,800 | -95,100 | -35,500 | 168,600 | 39,300 |
| Beginning Cash Position | 2,818,600 | 2,818,600 | 2,818,600 | 2,067,000 | 2,067,000 |
| End Cash Position | 3,369,000 | 3,223,600 | 2,460,200 | 2,818,600 | 2,380,800 |
| Net Cash Flow | $550,400 | $405,000 | $-358,400 | $751,600 | $313,800 |
| Free Cash Flow | |||||
| Operating Cash Flow | 6,344,100 | 2,632,200 | 1,166,000 | 4,240,100 | 4,552,000 |
| Capital Expenditure | -3,561,800 | -2,211,100 | -986,300 | -3,447,600 | -2,377,000 |
| Free Cash Flow | 2,782,300 | 421,100 | 179,700 | 792,500 | 2,175,000 |